A compilation of articles, news, study results and other updates in the field of gynecologic oncology.
Entries with titles highlighted in red may be of particular interest to survivors, caregivers or the general public.
FDA approves niraparib for first-line maintenance of advanced ovarian cancer
April 29, 2020: US Food & Drug Administration – On April 29, 2020, the Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. Read more.
Coverage of the SGO 2020 Annual Meeting
April 24, 2020: View various articles and interviews covering abstracts from the SGO 2020 Annual Meeting. Read articles from Targeted Oncology. Read articles from Onc Live.
Sexually transmitted infections and risk of ovarian cancer
April 23, 2020: Contemporary OB/GYN – A European nested case-control study suggests that Chlamydia trachomatis and herpes simplex virus 2 (HSV-2) may play a role in development of certain types of ovarian cancer. Read more.
Gene signature found for poor response to standard chemotherapy in rare uterine cancer
April 22, 2020: EurekAlert! -Women who don’t survive a rare and aggressive uterine cancer called uterine serous carcinoma, have high expression of a group of 73 genes, a score scientists say can help identify these women and improve their outcome. Read more.
New Standard in Recurrent, Platinum-Sensitive Ovarian Cancer
April 21, 2020: MedPage Today – Pegylated liposomal doxorubicin unseats gemcitabine in standard platinum regimen. Read more.
Olaparib Matches Chemotherapy Outcomes in Platinum-Sensitive Recurrent Ovarian Cancer
April 17, 2020: Targeted Oncology – Treatment with olaparib demonstrated similar outcomes to standard-of-care chemotherapy treatment in patients with BRCA wild-type, platinum-sensitive, recurrent epithelial ovarian cancer in the phase II CLIO study. Read more.
Drug overcomes chemotherapy resistance in ovarian cancer
April 16, 2020: EurekAlert! – Low dose of 2-deoxy-D-glucose shows success in treating clear cell ovarian cancer. Read more.
Niraparib Grabs Regulatory Attention in China for Treatment of Advanced Ovarian Cancer
April 16, 2020: Targeted Oncology – Niraparib was granted Priority Review in China as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, by the National Medical Products Administration. Read more.
Balstilimab, Potential Cervical Cancer Treatment, Placed on Fast Track
April 14, 2020: Immuno-oncology News – The U.S. Food and Drug Administration (FDA) has now given fast track status to Agenus’ balstilimab — both alone and in combination — as an immunotherapy candidate for advanced metastatic cervical cancer. Read more.
Water-Only Fasting May Reduce Chemo Modifications, Hospital Admissions
April 8, 2020: Medscape – Patients with gynecologic malignancies who consumed only water for 24 hours before and 24 hours after each chemotherapy cycle had fewer dose delays and reductions compared with patients who didn’t fast, results of a small study showed. Read more.
How Long Is It Safe to Delay Gynecologic Cancer Surgery?
March 26, 2020: Medscape – We know that untreated cancer is life threatening, but there is a difference between untreated and delayed. What is a safe time to wait for gynecologic cancer surgery after diagnosis without negatively affecting survival from that cancer. Read more.
Investigational Anti-Cancer Agent Elicits Responses in Platinum-Resistant Ovarian Cancer
March 26, 2020: Targeted Oncology – Treatment with an investigational targeted anti-cancer gene-therapy agent, VB-111, in addition to paclitaxel met the pre-specified efficacy criterion of an absolute percentage advantage of 10% or higher CA-125 response rate in patients with platinum-resistant ovarian cancer, according to results from the planned interim analysis of the phase III OVAL trial. Read more.
PARP Inhibitor Becomes Standard of Care for Advanced Ovarian Cancer Subset
February 7, 2020: Oncology Nursing News – Frontline niraparib (Zejula) is the new standard of care for patients with newly diagnosed, platinum-sensitive advanced ovarian cancer, after the positive results from the phase III PRIMA trial, explained Antonio González-Martín, MD, lead author in the study. Read more.
World Health Organization Outlines Plan to Eliminate Cervical Cancer in Low to Middle Income Countries
February 5, 2020: Cure – The World Health Organization (WHO) has announced its plans for eliminating cervical cancer as a public health problem among low-income to middle-income countries by fully vaccinating 90% of girls by 15 years old, screen 70% of women between the ages of 35 and 45 and provide 90% of patients with disease receiving care. The organization believes not only will this eliminate cervical cancer in these regions within this century, but also prevent millions of deaths, according to two modeling analyses published in The Lancet. Read more.
MEK/PI3K Inhibitor Combo Generates Activity in RAS/BRAF-Mutant Ovarian Cancer
February 4, 2020: Targeted Oncology – Continuous dosing of the MEK inhibitor binimetinib (Mektovi) plus buparlisib (BKM120), a PI3K inhibitor, demonstrated promising activity as treatment of patients with ovarian cancer harboring either a RAS or BRAF mutation, according to results from a phase Ib clinical trial (NCT01363232). Read more.
ASCO Guideline: Germline Testing Recommended for All Women Diagnosed With Epithelial Ovarian Cancer
February 4, 2020: Cancer Therapy Advisor – A retrospective study showed improved survival among patients with ovarian cancer treated with beta-
All women with a diagnosis of epithelial ovarian cancer should be offered testing for specific germline mutations, according to a new recommendation from ASCO. Read more.
Cervical cancer elimination ‘could be achieved’ by 2120
February 3, 2020: Healio – High HPV vaccination coverage for girls and scaled-up screening and treatment may lead to the elimination of cervical cancer in most lower-middle-income countries over the next 100 years, according to results of two modeling studies published in The Lancet. Read more.
Women’s wellness: researchers look at post menopause as key factor in endometrial cancer
February 3, 2020: Medical Xpress – Endometrial cancer is the most common gynecological malignancy in the U.S. and the fourth most common cancer among women. In addition, endometrial cancer incidence rates are on the rise in the western world, suggesting that alterations in environmental factors such as diet, lifestyle, and the vaginal microbiome may be important drivers in its cause. Read more.
Ipilimumab Shows Tolerability and Signals Efficacy in Advanced Cervical Cancer
January 28, 2020: Targeted Oncology – The phase I study of sequential ipilimumab (Yervoy) after chemoradiotherapy as a curative-intent treatment of patients with node-positive cervical cancer included 34 female patients with stage Ib2 to VI cervical cancer with positive pelvic lymph nodes, para-aortic lymph nodes, or both. Read more.
Use of intrauterine devices may decrease risk for ovarian cancer
January 21, 2020: Healio – Previous studies have linked the use of intrauterine devices (IUDs) to reduced risk for cervical and uterine cancer. Based on these findings, Saketh R. Guntupalli, MD, associate professor and director of the division of gynecologic oncology at University of Colorado School of Medicine, and colleagues examined the possible correlation between IUD use and risk for ovarian cancer. Read more.
Is it still reasonable to offer MIS hysterectomy? No.
January 20, 2020: Contemporary OB/GYN – Dr. Amanda Nickles Fader discusses the con side of the MIS argument from the LACC trial controversy. Read more.
Is it still reasonable to offer MIS hysterectomy? Yes.
January 20, 2020: Contemporary OB/GYN – Dr. Wendell Nauman discusses the pro side of the MIS argument from the LACC trial controversy. Read more.
While survival rates soar for other cancers, funding gaps limit progress on cervical and uterine cancer
January 10, 2020: The Verge – There are limited treatment advances for aggressive forms of these diseases. Read more.
Keytruda Approved for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer
January 9, 2020: Cancer Therapy Advisor – The Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. Read more.